IRIS Institutional Research Information System - AIR Archivio Istituzionale della Ricerca

BRANCACCIO, DIEGO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 10.320
NA - Nord America 7.055
AS - Asia 6.606
SA - Sud America 637
AF - Africa 125
OC - Oceania 46
Continente sconosciuto - Info sul continente non disponibili 5
Totale 24.794
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.790
GB - Regno Unito 4.409
CN - Cina 2.144
SG - Singapore 1.893
IT - Italia 1.357
DE - Germania 1.196
SE - Svezia 795
RU - Federazione Russa 713
HK - Hong Kong 519
VN - Vietnam 462
FR - Francia 419
BR - Brasile 398
IN - India 396
UA - Ucraina 356
TR - Turchia 309
NL - Olanda 275
KR - Corea 274
IE - Irlanda 249
EU - Europa 202
FI - Finlandia 185
BD - Bangladesh 167
CA - Canada 127
CO - Colombia 90
JP - Giappone 85
ID - Indonesia 81
GR - Grecia 77
AR - Argentina 59
MX - Messico 53
PL - Polonia 44
BE - Belgio 36
ES - Italia 32
IQ - Iraq 32
CI - Costa d'Avorio 31
SA - Arabia Saudita 31
NO - Norvegia 30
AU - Australia 29
CL - Cile 25
TH - Thailandia 24
CH - Svizzera 22
TW - Taiwan 22
RO - Romania 19
NI - Nicaragua 18
PH - Filippine 18
PK - Pakistan 18
ZA - Sudafrica 18
EC - Ecuador 17
NZ - Nuova Zelanda 17
IR - Iran 16
MY - Malesia 16
PE - Perù 16
CZ - Repubblica Ceca 14
EG - Egitto 14
TN - Tunisia 14
VE - Venezuela 14
PT - Portogallo 13
CR - Costa Rica 12
DK - Danimarca 12
IL - Israele 12
MA - Marocco 12
UZ - Uzbekistan 11
AE - Emirati Arabi Uniti 10
UY - Uruguay 10
AT - Austria 9
LB - Libano 9
HN - Honduras 8
LU - Lussemburgo 8
AZ - Azerbaigian 7
DO - Repubblica Dominicana 7
ET - Etiopia 7
LT - Lituania 7
GE - Georgia 6
GT - Guatemala 6
NG - Nigeria 6
PY - Paraguay 6
RS - Serbia 6
TT - Trinidad e Tobago 6
JM - Giamaica 5
JO - Giordania 5
KE - Kenya 5
KZ - Kazakistan 5
SK - Slovacchia (Repubblica Slovacca) 5
AL - Albania 4
BB - Barbados 4
BG - Bulgaria 4
LK - Sri Lanka 4
LV - Lettonia 4
MD - Moldavia 4
NP - Nepal 4
SV - El Salvador 4
AM - Armenia 3
BA - Bosnia-Erzegovina 3
BH - Bahrain 3
HU - Ungheria 3
KH - Cambogia 3
MU - Mauritius 3
SD - Sudan 3
SI - Slovenia 3
TL - Timor Orientale 3
BO - Bolivia 2
BY - Bielorussia 2
Totale 24.945
Salva come PNG Salva come JPEG
Città #
Southend 4.132
Singapore 1.081
Chandler 576
Ashburn 553
Hong Kong 486
Seattle 457
Beijing 453
San Jose 451
Milan 356
Princeton 312
Jacksonville 309
Wilmington 248
Dublin 247
Hanover 240
Council Bluffs 216
Dallas 209
Redmond 191
Bengaluru 172
Mountain View 172
Santa Clara 161
Nanjing 155
Fairfield 153
Ann Arbor 143
Lauterbourg 134
Los Angeles 134
Boardman 133
Munich 124
Woodbridge 119
Hanoi 118
Sakarya 118
Ho Chi Minh City 115
Andover 108
Shanghai 106
Houston 104
New York 101
Serra 100
Des Moines 98
Somerville 98
Buffalo 97
Guangzhou 86
Hefei 83
Dearborn 76
Athens 73
Bogotá 73
Frankfurt am Main 70
Berlin 65
Moscow 65
Toronto 63
Tianjin 60
Phoenix 53
Columbus 50
Tokyo 50
Rome 49
The Dalles 46
Cangzhou 45
Cambridge 44
Hangzhou 44
Jinan 42
São Paulo 42
Changsha 40
Helsinki 38
Jersey City 38
Nanchang 38
Redwood City 38
Eitensheim 37
Shenyang 37
Hebei 35
Bühl 34
Bologna 33
Warsaw 32
Abidjan 31
Brussels 31
Fuzhou 30
Jakarta 30
Seoul 30
Dong Ket 26
Sunnyvale 26
Kent 25
Mumbai 25
Shenzhen 24
Turin 24
Chicago 22
Verona 22
Palermo 21
Zhengzhou 20
Jiaxing 19
Naples 19
Nürnberg 19
San Diego 19
Da Nang 17
Quanzhou 17
Bangkok 16
Istanbul 16
Petina 16
Stavanger 16
Wuhan 16
Chengdu 15
Kiez 15
Kunming 14
Auburn Hills 13
Totale 15.493
Salva come PNG Salva come JPEG
Nome #
Pathogenesis of secondary hyperparathyroidism 735
Chelanti del fosforo a base di ferro : quali nuovi vantaggi? = Iron-based Phosphate Binders for ESRD Patients 573
Retromer stabilization results in neuroprotection in a model of Amyotrophic Lateral Sclerosis 499
Nuove acquisizioni nella patogenesi dell'iperparatiroidismo secondario = New insights in the pathogenesis of secondary hyperparathyroidism 372
Isolation and growth of smooth muscle-like cells derived from tuberous sclerosis complex-2 human renal angiomyolipoma : epidermal growth factor is the required growth factor 347
VDRA therapy is associated with improved survival in dialysis patients with serum intact PTH ≤ 150 pg/mL: results of the Italian FARO Survey 339
Lanthanum Prevents High Phosphate-Induced Vascular Calcification by Preserving Vascular Smooth Muscle Lineage Markers 322
Management of calcium refilling post - parathyroidectomy in end-stage renal disease 317
Prevenzione delle calcificazioni extrascheletriche nel paziente uremico 310
Importance of vitamin D receptor activation in clinical practise 297
Bone geometry, biomechanics, and mineral content of the distal radius in uremic patients with severe hyperparathyroidism =[Valutazione delle proprietà  geometriche, biomeccaniche e osteodensitometriche del radio ultradistale mediante Tomografia Computerizzata quantitativa periferica nei pazienti uremici affetti da iperparatiroidismo grave 294
Clinical significance of FGF-23 measurement in dialysis patients 292
Cardiac and pulmonary calcification in a hemodialysis patient: partial regression 4 years after parathyroidectomy 275
End-stage renal disease costs for patients new to hemodialysis in Italy: The FARO-2 Study 274
The combination of lanthanum chloride and the calcimimetic calindol delays the progression of vascular smooth muscle cells calcification 271
Work ability and health status in dialysis patients 270
Facial changes in adult uremic patients on chronic dialysis: possible role of hyperparathyroidism 261
Abnormal variations in the facial soft tissues of adult uremic patients on chronic dialysis 254
Effort-Reward Imbalance, Workabilty and Utility Estimates in Chronic Kidney Failure 242
Arterial accelerated aging in dialysis patients: the clinical impact of vascular calcification 231
Effect of VDRA on survival in incident hemodialysis patients: results of the FARO-2 observational study 230
CKD-MBD : an endless story 229
Combined effects of ascorbic acid and phosphate on rat VSMC osteoblastic differentiation 227
How to avoid and manage a pneumothorax 219
Vascular calcification in chronic kidney disease : a changing scenario 219
Management of secondary hyperparathyroidism in the elderly patient with chronic kidney disease 218
Pathogenesis and treatment of vascular calcification in CKD 218
Prevenzione e trattamento dell’iperparatiroidismo secondario nel paziente con malattia renale cronica allo stadio 3-5 non in dialisi 218
Management of secondary hyperparathyroidism in uremic patients : the role of the new vitamin D analogs 217
A role for enhanced integrin and FAK expression in uremia-induced parathyroid hyperplasia 217
Isolation and growth characterization of two types of human TSC2 gene-deficient cells 216
The Calcimimetic Calindol Prevents High Phosphate-Induced Vascular Calcification by Upregulating Matrix GLA Protein 216
Achievement of NKF/K-DOQI recommended target values for bone and mineral metabolism in incident hemodialysis patients : results of the FARO-2 Cohort 214
Vitamin D: physiology and pathophysiology 212
Blood pressure, proteinuria, and phosphate as risk factors for progressive kidney disease : a hypothesis 212
Calcificazioni cardiovascolari e aterosclerosi accelerata in corso di uremia 210
Transient decrease of serum bicarbonate levels with Sevelamer hydrochloride as the phosphate binder 206
Pathogenesis and treatment of secondary hyperparathyroidism in dialysis patients : the role of paricalcitol 204
Evaluating targets and costs of treatment for secondary hyperparathyroidism in incident dialysis patients: the FARO-2 study 204
Vitamin D retains an important role in the pathogenesis and management of secondary hyperparathyroidism in chronic renal failure 203
Therapeutic options for mineral metabolism disorders in dialysis patients: a case report 198
Occupational stress is associated with impaired work ability and reduced quality of life in patients with chronic kidney failure 197
The bone-vasculature-axis interaction: new insights into the pathogenesis of vascular calcification 195
Treatment of hyperparathyroidism-why is it crucial to control serum phosphate? 195
Low-molecular-weight heparins should be used with caution in patients with chronic kidney disease 194
Emerging role for the vitamin D receptor activator (VDRA), paricalcitol, in the treatment of secondary hyperparathyroidism 194
Cardiovascular calcification and accelerated atherosclerosis in chronic kidney disease 193
Osteonecrosi avascolare mandibolare in un paziente in trattamento emodialitico sostitutivo trattato con bifosfonati 191
Encephalopathy in a dialysis patient treated with lanthanum carbonate (LC) 191
Minimal laboratory investigation of uremic patients. 189
Impaired brachial artery endothelial flow-mediated dilation and orthostatic stress in hemodialysis patients 188
Awareness of hypertension and proteinuria in randomly selected patients in 11 Italian cities. A 2005 report of the National Kidney Foundation of Italy 187
Preventive measures and new pharmacological approaches of calcium and phosphate disorders 184
The continuous challenge of cardiovascular and bone and bone disease in uremic patients: clinical consequences of hyperphosphatemia and advanced therapeutic approaches 184
A critical role for enhanced TGF-alpha and EGFR expression in the initiation of parathyroid hyperplasia in experimental kidney disease 184
Anticoagulation in dialysis patients with central venous catheters: a word of caution 183
New acquisitions in therapy of secondary hyperparathyroidism in chronic kidney disease and peritoneal dialysis patients : role of vitamin D receptor activators 183
The Quality of Life, Work Ability and working conditions of Hemodialysis patients 180
Peritoneal dialysis catheter advances 178
Calcium and phosphate handling in peritoneal dialysis 177
Secondary hyperparathyroidism in chronic dialysis patients : results of the Italian FARO survey on treatment and mortality 176
Serum fetuin-A levels link inflammation and cardiovascular calcification in hemodialysis patients 174
Safety concerns on the use of low molecular weight heparin in dialysis patients 172
Vascular calcification and cardiovascular outcome in dialysis patients : the role of gene polymorphisms 172
Bone disease in uremic patients : advances in PTH suppression 172
Matrix GLA protein gene polymorphisms : clinical correlates and cardiovascular mortality in chronic kidney disease patients 171
An interesting meeting 170
Gene polymorphisms and serum fetuin-A (AHSG) levels in haemodialisys (HD) patients 165
Comparison Of Sevelamer HCl And Calcium Carbonate In The Treatment Of Hyperphosphatemia In Dialysis Patients: A Randomized Clinical Trial - Calcium Carbonate Sevelamer Evaluation (CaCSE) Study 165
Pathogenesis of parathyroid hyperplasia in renal failure 164
Ingrandimento delle ghiandole salivari da mezzo di contrasto iodato endovenoso. Descrizione di un caso 164
Peritoneal dialysis catheters : New catheters are desperately needed 163
Inflammation and vascular calcification in chronic kidney disease: the role of Fetuin-A 163
Dialysis amyloidosis with massive popliteal deposition of beta 2-microglobulin amyloid 163
The mechanism of calcium deposition in soft tissues 161
Decreased serum fetuin-A levels after a single haemodialysis session 159
Progression of coronary artery calcification in predialysis patients 158
Magnetic resonance imaging of renal involvement in genetically studied patients with tuberous sclerosis complex 158
Role of Fetuin−A in Dialysis Patients: A Potential Link between Vascular Calcification and Microinflammation. 158
Deposition of kappa and lambda light chains in amyloid filaments of dialysis-related amyloidosis 158
Role of Lipoylation of the Immunodominant Epitope of Pyruvate Dehydrogenase Complex : Toward a Peptide-Based Diagnostic Assay for Primary Biliary Cirrhosis 158
Pharmacological control of secondary hyperparathyroidism in hemodialysis subjects: a cost consequences analysis of data from the FARO study 157
CKD Patients : The Dilemma of Serum PTH Levels 153
Vitamin D receptor activator selectivity in the treatment of secondary hyperparathyroidism : understanding the differences among therapies 152
Vascular calcification in uremic conditions : new insights into pathogenesis 152
Mechanism of uremic osteodystrophy and prevention of hyperparathyroidism in the uremic patient 152
Design, synthesis and characterization of aryl bis-guanyl hydrazones as RNA binders of C9orf72 G4C2 extended repeats 151
VDRAs versus calcimimetics : better safe than sorry? 151
The role of the vascular access coordinator. An example of co-operation between physicians and nurses 151
Inequalities in transplant waiting list activation across Italian dialysis centers 150
Hyperphosphatemia in dialysis patients : the therapeutic role of lanthanum carbonate 149
Pathogenesis of vascular calcification in chronic kidney disease 148
Fetuin-A gene expression, synthesis and release in primary human hepatocytes cultured in a galactosylated membrane bioreactor 145
Serum osteoprotegerin levels are associated with increased aortic calcification in dialysis patients 144
Calcium and phosphate plasma levels in dialysis patients after dietary Ca-P overload. Role of gastric acid secretion 144
Nothing really matters 143
Matrix metalloproteinase-1 and matrix metalloproteinase-3 gene promoter polymorphisms are associated with mortality in haemodialysis patients 143
Ultrastructural localization of advanced glycation end products and beta2-microglobulin in dialysis amyloidosis 142
Gene polymorphisms and serum alpha-2-Heremans-Schmid levels in Italian haemodialysis patients 140
Aluminum-dependent transfusions in dialysis 140
Totale 21.120
Salva come PNG Salva come JPEG
Categoria #
all - tutte 61.207
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 61.207
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021568 0 0 0 0 0 0 0 0 0 0 473 95
2021/20221.842 179 51 83 103 124 178 233 104 170 171 148 298
2022/20232.087 281 165 171 282 264 387 38 124 225 38 85 27
2023/20241.265 36 107 80 54 224 112 52 67 64 115 145 209
2024/20252.911 137 272 79 315 239 98 102 336 147 241 283 662
2025/20265.913 602 370 633 415 648 443 816 373 720 477 416 0
Totale 26.044